肾移植后抗semaphorin 3B介导的膜性肾病复发
本文报告一例7岁男孩在肾移植后25天出现抗semaphorin 3B抗体介导的膜性肾病早期复发,表现为肾病范围蛋白尿,肾活检证实组织学复发且semaphorin 3B抗原与IgG共定位,接受利妥昔单抗治疗后40天抗semaphorin 3B抗体转阴。
要点
- 抗semaphorin 3B抗体相关膜性肾病可在肾移植后早期(25天)复发。
- 移植时检出抗semaphorin 3B抗体,利妥昔单抗治疗后40天抗体转阴。
- 该病例提示抗semaphorin 3B抗体具有致病性,应监测相关患者。
核心结论
- 该病例提供证据表明抗semaphorin 3B抗体具有致病性,应在膜性肾病患者中监测。
研究设计与样本
- 病例报告:对1例7岁男孩的天然肾及移植后1个月和5个月进行肾活检,用免疫组化和共聚焦显微镜检测semaphorin 3B抗原,用Western blot检测并序贯分析抗semaphorin抗体。
主要发现
- 患儿表现为严重肾病综合征和晚期肾衰竭,无遗传性或相关自身免疫病证据。
- 电镜见大量几乎融合的沉积物,semaphorin 3B抗原呈明亮颗粒状上皮下染色。
- 血清Western blot分析检出抗semaphorin 3B抗体。
- 移植后25天膜性肾病复发,表现为肾病范围蛋白尿,肾活检证实组织学复发且semaphorin 3B抗原与IgG共定位。
- 患者接受利妥昔单抗治疗,移植时检出的抗semaphorin 3B抗体在利妥昔单抗治疗后40天未检出。
临床怎么用
- 作者认为抗semaphorin 3B抗体具有致病性,应在膜性肾病患者中监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Membranous nephropathy (MN) is rare in pediatric patients, although its diagnosis may be underestimated in children who are responsive to corticosteroid therapy prescribed for a suspicion of minimal change disease. It is most often associated with an autoimmune disease, predominantly lupus. We previously reported the occurrence of early-onset MN associated with semaphorin 3B in nine children and two adults. METHODS: Biopsies were performed on native kidney and at 1 and 5 months after transplantation. Semaphorin 3B antigen was detected in immune deposits by immunohistochemistry and confocal microscopy on paraffin-embedded biopsies. Anti-semaphorin antibodies were detected by Western blot and analyzed sequentially. RESULTS: We report the first case of early recurrence after transplantation in a 7-year-old boy who presented with severe nephrotic syndrome and advanced kidney failure. There was no evidence of hereditary or associated autoimmune disease. Abundant, almost coalescent deposits were seen by electron microscopy and bright granular, subepithelial staining was observed for semaphorin 3B antigen. Western blot analysis of serum revealed anti-semaphorin 3B antibodies. Recurrence of MN occurred 25 days after transplantation and manifested as nephrotic range proteinuria despite conventional immunosuppressive therapy. Kidney biopsies confirmed histologic MN recurrence with colocalization of semaphorin 3B antigen and IgG. The patient was treated with rituximab. Anti-semaphorin 3B antibodies, which were detected at transplantation, were not detected 40 days after rituximab. CONCLUSION: This case provides evidence that anti-semaphorin 3B antibodies are pathogenic and should be monitored in patients with MN.
引用
- Fila M, Debiec H, Perrochia H, et al. Recurrence of Anti-Semaphorin 3B-Mediated Membranous Nephropathy after Kidney Transplantation. J Am Soc Nephrol. 2022. PMID: 35017170. doi:10.1681/ASN.2021101323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。